The current WHO classification includes the entity “diffuse low-grade glioma, MAPK pathway-altered”, which is defined by genetic alterations in BRAF and FGFR1. Moreover, circumscribed astrocytic gliomas include “high-grade astrocytomas with piloid features” with recurrent MAPK (NF1, FGFR1) alterations [3, 5]. This evidence concerns the gene FGFR1 and astrocytoma (excluding glioblastoma).